NAC cycles | DFS | OS | ||||
---|---|---|---|---|---|---|
Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |||
Overall§ | ||||||
Non-standard cycles | Ref | Ref | ||||
Standard cycles | 0.62 (0.44, 0.88) | 0.007* | 0.54 (0.37, 0.79) | 0.001* | ||
HR positive/HER2 negative† | ||||||
Non-standard cycles | Ref | Ref | ||||
Standard cycles | 0.72 (0.35, 1.52) | 0.393 | 0.63 (0.29, 1.40) | 0.255 | ||
HER2 positive† | ||||||
Non-standard cycles | Ref | Ref | ||||
Standard cycles | 0.59 (0.36, 0.96) | 0.033* | 0.49 (0.28, 0.86) | 0.012* | ||
Triple negative† | ||||||
Non-standard cycles | Ref | Ref | ||||
Standard cycles | 0.50 (0.25, 0.98) | 0.043* | 0.45 (0.22, 0.91) | 0.026* |
*P < 0.05 was considered statistically significant.
§Adjusted for neoadjuvant chemotherapy cycles, age at diagnosis, clinical tumor stage, biological subtypes, and post-neoadjuvant pathological node stage.
†Adjusted for neoadjuvant chemotherapy cycles, age at diagnosis, clinical tumor stage, and post-neoadjuvant pathological node stage.
HR, hormone receptor; HER2, human epidermal growth factor receptor-2; pCR, pathological complete response; NAC, neoadjuvant chemotherapy; DFS, disease-free survival; OS, overall survival.